APAC CIOOutlook

Advertise

with us

  • Technologies
      • Artificial Intelligence
      • Big Data
      • Blockchain
      • Cloud
      • Digital Transformation
      • Internet of Things
      • Low Code No Code
      • MarTech
      • Mobile Application
      • Security
      • Software Testing
      • Wireless
  • Industries
      • E-Commerce
      • Education
      • Logistics
      • Retail
      • Supply Chain
      • Travel and Hospitality
  • Platforms
      • Microsoft
      • Salesforce
      • SAP
  • Solutions
      • Business Intelligence
      • Cognitive
      • Contact Center
      • CRM
      • Cyber Security
      • Data Center
      • Gamification
      • Procurement
      • Smart City
      • Workflow
  • Home
  • CXO Insights
  • CIO Views
  • Vendors
  • News
  • Conferences
  • Whitepapers
  • Newsletter
  • Awards
Apac
  • Artificial Intelligence

    Big Data

    Blockchain

    Cloud

    Digital Transformation

    Internet of Things

    Low Code No Code

    MarTech

    Mobile Application

    Security

    Software Testing

    Wireless

  • E-Commerce

    Education

    Logistics

    Retail

    Supply Chain

    Travel and Hospitality

  • Microsoft

    Salesforce

    SAP

  • Business Intelligence

    Cognitive

    Contact Center

    CRM

    Cyber Security

    Data Center

    Gamification

    Procurement

    Smart City

    Workflow

Menu
    • Cyber Security
    • Hotel Management
    • Workflow
    • E-Commerce
    • Business Intelligence
    • MORE
    #

    Apac CIOOutlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIOOutlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    Iaso Biotherapeutics Bags $60M in Series B Round of Financing

    Iaso Biotherapeutics, a leading Nanjing, China-based clinical-stage biotechnology company, secures funding worth $60 million from its Series B round of Financing. GL Ventures led the Series B round.  

    Iaso Biotherapeutics Bags $60M in Series B Round of Financing

    By

    Apac CIOOutlook | Monday, April 13, 2020

    Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

    Iaso Biotherapeutics secures $60M funding for the expansion of its product pipeline 

    FREMONT, CA: Iaso Biotherapeutics, a leading Nanjing, China-based clinical-stage biotechnology company, secures funding worth $60 million from its Series B round of Financing. GL Ventures led the Series B round. 

    The clinical-stage biotechnology company focuses the fund utilization mainly on the expansion of its product pipeline and enhancing the progress rate of the current projects ( including the regulatory applications and clinical trials in China and the US). It also aims further to advance the technology of a fully-human antibody development platform, encourage co-operations with international research and development institutions, and accelerate the development of commercial facilities. 

    From its inception in 2017, Iaso Biotherapeutics has been a clinical-stage biotechnology company that was dedicated wholly to the development of innovative cell therapies to cure cancer. The company is simultaneously developing more than ten pipeline products, focusing more on autologous and universal CAR-T products for hematological tumors. All products of the company are based on the fully human sequence. Additional development efforts comprise of unique TCR-like CAR-T cell therapy products for solid tumor indications such as viral infection related gastric cancer and nasopharyngeal carcinoma. 

    Iaso Bio also owns a proprietary phage display library(>2×1011) that supports the demand for fully-human antibodies necessary for CAR-T and lays the foundational for the development of antibody-drug pipelines as well. The company's in-house plasmid, lentivirus, and CAR-T production technology platforms fulfill the requirements of IND submissions and clinical research for numerous products. In 2019, September, the company obtained the NMPA approval of phase lb/II IND application for CT103A, an anti-BCMA CAR-T co-developed in association with Innovent Biologics for treating the relapsed refractory multiple myeloma (rr/mm). Additionally, many new drug candidates have entered the pre-clinical stage or are involved in investigator-initiated clinical trials with various drugs expected to enter clinical trials in the next few years. 

    Check out: Top Bioinformatics Solution Companies

    More in News

    Real-Time Insights Fueling Smarter Brand Strategies

    Real-Time Insights Fueling Smarter Brand Strategies

    Transforming Retail: The Impact of VR and AR in Asia Pacific

    Transforming Retail: The Impact of VR and AR in Asia Pacific

    Enhancing Customer Satisfaction through Omni-Channel Payments

    Enhancing Customer Satisfaction through Omni-Channel Payments

    AI's Role in Apac's Digital Transformation Journey

    AI's Role in Apac's Digital Transformation Journey

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Copyright © 2025 APAC CIOOutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    Home |  CXO Insights |   Whitepapers |   Subscribe |   Conferences |   Sitemaps |   About us |   Advertise with us |   Editorial Policy |   Feedback Policy |  

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/iaso-biotherapeutics-bags-60m-in-series-b-round-of-financing--nwid-7424.html